-
公开(公告)号：US10774086B2
公开(公告)日：2020-09-15
申请号：US16463451
申请日：2017-11-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Richard A. Hartz , Vijay T. Ahuja , Prasanna Sivaprakasam , Gene M. Dubowchik , John E. Macor
IPC: A61K31/5025 , C07D487/04
Abstract: The disclosure generally relates to compounds of formula (I), including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.
-
公开(公告)号：US10752609B2
公开(公告)日：2020-08-25
申请号：US16463467
申请日：2017-11-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Richard A. Hartz , Vijay T. Ahuja , Guanglin Luo , Ling Chen , Prasanna Sivaprakasam , Gene M. Dubowchik , Swanee E. Jacutin-Porte , John E. Macor
IPC: C07D401/12 , A61P25/28 , C07D401/14 , C07D403/12 , C07D405/14 , C07D417/14
Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.
-
公开(公告)号：US20190276463A1
公开(公告)日：2019-09-12
申请号：US16463451
申请日：2017-11-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Richard A. Hartz , Vijay T. Ahuja , Prasanna Sivaprakasam , Gene M. Dubowchik , John E. Macor
IPC: C07D487/04
Abstract: The disclosure generally relates to compounds of formula (I), including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.
-
公开(公告)号：US12097241B2
公开(公告)日：2024-09-24
申请号：US17573238
申请日：2022-01-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
CPC classification number: A61K38/18 , A61K38/2221 , C07K1/1077 , C07K14/64 , A61K38/00 , A61K45/06 , A61K47/64 , A61P9/00
Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
公开(公告)号：US20220211812A1
公开(公告)日：2022-07-07
申请号：US17573238
申请日：2022-01-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
Patent Agency Ranking
公开(公告)号：US20210196791A1
公开(公告)日：2021-07-01
申请号：US17198939
申请日：2021-03-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
公开(公告)号：US10266578B2
公开(公告)日：2019-04-23
申请号：US15891492
申请日：2018-02-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
公开(公告)号：US20220331402A1
公开(公告)日：2022-10-20
申请号：US17721569
申请日：2022-04-15
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
公开(公告)号：US11224634B2
公开(公告)日：2022-01-18
申请号：US17198939
申请日：2021-03-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
10.发明授权公开(公告)号：US11185570B2
公开(公告)日：2021-11-30
申请号：US16287342
申请日：2019-02-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.029 seconds)
